

SYNTHESIS AND CYTOTOXICITY OF METAL 4-METHYL-8-QUINOLINETHIOLATES


E. Lukevics¹, I. Shestakova¹, I. Domracheva¹, E. Yashchenko¹,
D. Zaruma², and J. Ashaks²

It has been shown that the introduction of a methyl group at position 4 of the quinoline ring in metal 8-quinolinethiolates brings about a significant increase in the selectivity of their cytotoxic activity. It was found that rhodium 4-methyl-8-quinolinethiolate is 46 times less toxic than the unsubstituted 8-quinolinethiolate but with comparable toxicity towards MG-22A tumor cells (LC_{50} 2 $\mu\text{g/ml}$).

Keywords: 4-methyl-8-quinolinethiolates of copper iridium, osmium, palladium, platinum, rhodium, ruthenium; synthesis, toxicity, cytotoxicity.

Many organic derivatives of copper [1], ruthenium [2], rhodium [3], and palladium [4] containing a metal to sulfur bond shown antitumor activity. We have shown that the 8-quinolinethiolates of copper, cadmium, indium, antimony, bismuth, ruthenium, rhodium, palladium, osmium, iridium, and platinum show high cytotoxicity towards HT-1080 (human fibrosarcoma), MG-22A (mouse hepatoma), and B-16 (mouse melanoma) cells [5]. The highest activity to HT-1080 was shown by the iridium complex and to the MG-22A by the osmium complex. However, all of the metal 8-quinolinethiolates studied proved highly toxic towards normal NIH 3T3 mouse embryonic fibroblasts [5].

The introduction of substituents in the quinoline ring allowed us to decrease the toxicity and increase the selectivity of di(8-quinolyl) disulfides [6] and also to decrease the toxicity of the analogous metal 8-quinolineselenolates through introduction of a 4-methyl group into the quinoline ring [7]. We have therefore synthesized a series of metal 4-methyl-8-quinolinethiolates **1a-g** (Table 1) with the aim of decreasing the toxicity of the highly active complexes and studied their cytotoxicity on two tumour cell lines HT-1080 and MG-22A as well as on normal NIH 3T3 fibroblasts which served as a toxicity measure of the compounds (alternative method of determining LD_{50} [8]).



1 a M = Cu, **b** M = Ru, **c** M = Rh, **d** M = Pd, **e** M = Os, **f** M = Ir, **g** M = Pt;
a,d,g $n = 2$, **b, c, e, f** $n = 3$

¹Latvian Institute of Organic Synthesis, Riga LV-1006; e-mail: sinta@osi.lv. ²RTU Institute of Inorganic Chemistry, Salaspils, LV-2169; e-mail: nki@nki.lv. Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 5, pp. 755-758, May, 2007. Original article submitted March 29, 2007.

TABLE 1. Elemental Analysis and Yields of 4-Methyl-8-quinolinethiolates **1**.

Compound	Empirical formula	Found, % Calculated, %			Yield, %
		C	H	N	
1a	C ₂₀ H ₁₆ CuN ₂ S ₂	58.05	3.80	6.88	82
		58.30	3.91	6.80	
1b	C ₃₀ H ₂₄ N ₃ RuS ₃	57.50	3.75	6.61	70
		57.76	3.88	6.74	
1c	C ₃₀ H ₂₄ N ₃ RhS ₃	57.80	3.76	6.60	72
		57.59	3.87	6.72	
1d	C ₂₀ H ₁₆ N ₂ PdS ₂	52.52	3.63	6.28	85
		52.77	3.54	6.15	
1e	C ₃₀ H ₂₄ N ₃ OsS ₃	50.78	3.30	5.80	70
		50.54	3.39	5.90	
1f	C ₃₀ H ₂₄ IrN ₃ S ₃	50.20	3.27	5.76	70
		50.40	3.38	5.88	
1g	C ₂₀ H ₁₆ N ₂ PtS ₂	44.37	2.82	5.26	83
		44.18	2.97	5.15	

The introduction of a methyl group into position 4 of the quinoline ring decreases the toxicity of the metal 4-methyl-8-quinolinethiolates by more than one order when compared with that of the complexes with unsubstituted ligand [5]. This most significantly affects the toxicity of the iridium **1f** (LC₅₀ 85 µg/ml), rhodium **1c** (LC₅₀ 78 µg/ml), and palladium **1d** (LC₅₀ 40 µg/ml) complexes. The decrease in toxicity of the metal complexes **1a-g** can be ordered as follows (Table 2):

$$\text{Ru} > \text{Os} > \text{Pt} > \text{Cu} > \text{Pd} > \text{Rh} > \text{Ir}$$

The most toxic complexes of ruthenium **1b** and osmium **1e** also show the greatest cytotoxicity towards tumor cells. The MG-22A cells proved to be somewhat more sensitive to the action of these compounds than the HT-1080 cells. The palladium complex **1d** has the least cytotoxicity. The platinum **1g**, rhodium **1c**, and iridium **1f** complexes caused the death of tumor cells even at a low concentration (LC₅₀ ~ 2 µg/ml) while the rhodium and iridium 4-methyl-8-quinolinethiolates proved to be 6-7 times less toxic than the platinum complex **1b** in relation to normal fibroblasts.

It should be noted that the rhodium complex **1c** is 46 times less toxic than the corresponding unsubstituted 8-quinolinethiolate [5] but shows comparable cytotoxicity towards MG-22A tumor cells (LC₅₀ 2 µg/ml). Hence we have shown that the introduction of a methyl group into the 4-position of the quinoline ring in metal 8-quinolinethiolates leads to a marked increase in the selectivity of their cytotoxic action.

TABLE 2. Cytotoxicity of 4-Methyl-8-quinolinethiolates **1***

Compound	LC ₅₀ , µg/ml					LD ₅₀ , mg/kg
	HT-1080		MG-22A		3T3	
	CV	MTT	CV	MTT	NR	
1a	11	10	2	2	22	494
1b	3	2	<1	<1	4	293
1c	6	2	2	2	78	1063
1d	44	21	15	17	40	681
1e	1	<1	<1	1	10	427
1f	7	2	2	2	85	1142
1g	4	2	2	2	12	434

* CV = crystal-violet; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; NR = neutral-red.

EXPERIMENTAL

Elemental analysis was carried out using a Czechoslovakian CHN analyser.

4-Methyl-8-quinolinethiol Sodium Salt. $C_{10}H_8NSNa.H_2O$ was prepared by a known method [9].

Preparation of Metal 4-Methyl-8-quinolinethiolates (see Table 1). The 4-methyl-8-quinolinethiol sodium salt (0.2 g, 0.86 mmol) was dissolved in 80% ethanol (10 ml), acetate buffer solution (pH 5, 5 ml) added, and then a solution of the appropriate metal salt in water (5 ml) was added with stirring: $CuSO_4.5H_2O$ (0.1 g, 0.4 mmol), $K_2[Ru(H_2O)Cl_5]$ (0.1 g, 0.27 mmol), $(NH_4)_3[RhCl_6].2H_2O$ (0.1 g, 0.26 mmol), $PdCl_2$ (0.1 g, 0.13 mmol), K_2OsBr_6 (0.18 g, 0.24 mmol), $(NH_4)_3[IrCl_6].H_2O$ (0.12 g, 0.25 mmol), or K_2PtCl_4 (0.16 g, 0.38 mmol). In the case of the Ru, Rh, Os, Ir, and Pt salts the reaction mixture was heated for 5 min on a water bath. The precipitated metal 4-methyl-8-quinolinethiolates were filtered off, washed with water, dried in air, and recrystallized from chloroform,

Cytotoxicity of Compounds 1a-g (Table 2), and also the acute toxicity (LD_{50} , mg/kg) were determined by methods [6, 8].

REFERENCES

1. F. Gonzalez-Vilchez and R. Vilaplana, in: M. Gielen and E. R. T. Tiekink (editors), *Metallotherapeutic Drugs and Metal-Based Diagnostic Agents*, J. Wiley and Sons, Chichester (2005), p. 219.
2. O. Lentzen, C. Moucheron, and A. K. Mesmaeker, in: M. Gielen and E. R. T. Tiekink (editors), *Metallotherapeutic Drugs and Metal-Based Diagnostic Agents*, J. Wiley and Sons, Chichester (2005), p. 359.
3. F. P. Pruchnik, in: M. Gielen and E. R. T. Tiekink (editors), *Metallotherapeutic Drugs and Metal-Based Diagnostic Agents*, J. Wiley and Sons, Chichester (2005), p. 379.
4. A. Garoufis, S. K. Hadjikakou, and N. Hadjiliadis, in: M. Gielen and E. R. T. Tiekink (editors), *Metallotherapeutic Drugs and Metal-Based Diagnostic Agents*, J. Wiley and Sons, Chichester (2005), p. 399.
5. E. Lukevics, I. Shestakova, I. Domracheva, A. Nesterova, D. Zaruma, and J. Ashaks, *Khim. Geterotsikl. Soedin.* 870 (2006). [*Chem. Heterocycl. Comp.*, **42**, 761 (2006)].
6. E. Lukevics, I. Shestakova, I. Domracheva, E. Yashchenko, D. Zaruma, and J. Ashaks, *Khim. Geterotsikl. Soedin.* 750 (2007). [*Chem. Heterocycl. Comp.*, **43**, 629 (2007)].
7. E. Lukevics, I. Shestakova, I. Domracheva, A. Nesterova, J. Ashaks, and D. Zaruma, *Khim. Geterotsikl. Soedin.* 59 (2006). [*Chem. Heterocycl. Comp.*, **42**, 53 (2006)].
8. US Department of Health and Human Services, *Guidance Document on Using in vitro Data to Estimate in vivo Starting Doses for Acute Toxicity*, National Institute of Health (2001).
9. A. Sturis, J. Bankovsky, E. Lukša, and A. Ievinš, *Izv. Akad. Nauk Latv. SSR, Ser. Khim.*, 476 (1966).